發(fā)布時(shí)間：2018-01-20 12:10

  本文關(guān)鍵詞： 瑞舒伐他汀 依折麥布 腦梗死 動(dòng)脈粥樣硬化 血脂 hs-CRP　出處：《蘇州大學(xué)》2014年碩士論文　論文類型：學(xué)位論文

【摘要】：研究目的越來(lái)越多的臨床證據(jù)表明，高脂血癥是引起冠狀動(dòng)脈粥樣硬化性心臟病、腦血管疾病的主要致病危險(xiǎn)因素。在本研究中，通過(guò)對(duì)可定、益適純聯(lián)合調(diào)脂與可定單藥調(diào)脂效果及安全性的比較，探討更適合于腦梗死患者卒中二級(jí)預(yù)防用藥的調(diào)脂方案。 研究對(duì)象及方法選擇2012年6月1日至2013年6月30日在蘇州大學(xué)附屬第二醫(yī)院神經(jīng)內(nèi)科住院的腦梗死患者，均伴有頸動(dòng)脈粥樣硬化斑塊和高脂血癥（TC5.69mmol/L，LDL-C3.10mmol/L），，其中男性61例，女性37例；年齡48-71歲，平均61.32±7.36歲。所有患者入組前均未應(yīng)用他汀類與鹽酸類降脂藥物治療，均無(wú)肝腎功能異常，無(wú)急重癥感染、3個(gè)月內(nèi)無(wú)手術(shù)和外傷史，無(wú)代謝與內(nèi)分泌系統(tǒng)疾病，無(wú)惡性腫瘤病史，預(yù)計(jì)生存期均超過(guò)1年，2組患者的性別、年齡等一般臨床資料比較差異無(wú)統(tǒng)計(jì)學(xué)意義（P0.05），具有一致性。所有研究對(duì)象入院后均給予常規(guī)藥物治療，包括給予抗血小板聚集、降血壓(腦梗死急性期除外)類藥物，將所有入組的98例患者采用隨機(jī)數(shù)字法分為對(duì)照組（n=49）和觀察組（n=49）：對(duì)照組口服瑞舒伐他�。ㄆ访啥�，國(guó)藥準(zhǔn)字J20090091，阿斯利康制藥有限公司）10mg，1次/d，觀察組口服瑞舒伐他汀10mg+依折麥布（品名益適純，進(jìn)口藥品注冊(cè)證號(hào):H20080132，美國(guó)先靈葆雅制藥有限公司）10mg，1次/d，隨訪24周，分別在12周、24周于門(mén)診抽空腹血監(jiān)測(cè)血脂四項(xiàng)血清總膽固醇(TC)、甘油三酯（TG）、低密度脂蛋白膽固醇(LDL-C)、高密度脂蛋白膽固醇（HDL-C）、載脂蛋白B（Apo-B）、超敏C反應(yīng)蛋白（hs-CRP）、肝功能（谷丙轉(zhuǎn)氨酶ALT、谷草轉(zhuǎn)氨酶AST）、肌酸激酶（CK）值，并于24周在心超室行頸動(dòng)脈多普勒超聲檢查，測(cè)量頸總動(dòng)脈內(nèi)粥樣斑塊橫切面的最大面積（Smax），于距頸總動(dòng)脈分叉處1.0cm內(nèi)測(cè)量頸動(dòng)脈內(nèi)膜中層厚度(IMT)，記錄用藥后主要終點(diǎn)事件（死亡）及次要終點(diǎn)事件（新發(fā)腦卒中）。 結(jié)果2組治療后TC、TG、LDL-C和Apo-B水平均較治療前顯著減低（P＜0.05），觀察組LDL-C、TC和Apo-B的減低幅度明顯低于對(duì)照組（P＜0.05）。治療后觀察組頸動(dòng)脈粥樣斑塊最大面積較治療前明顯減�。≒＜0.05），對(duì)照組治療前、治療后頸動(dòng)脈粥樣斑塊面積無(wú)明顯變化（P＞0.05）。2組治療后hs-CRP水平均明顯減低（P＜0.05），觀察組與對(duì)照組比較無(wú)統(tǒng)計(jì)學(xué)差異（P＞0.05）。2組不良反應(yīng)發(fā)生率比較差異無(wú)統(tǒng)計(jì)學(xué)意義（P＞0.05）。 結(jié)論1.可定10mg或可定10mg+益適純10mg都能顯著降低血脂水平，但可定聯(lián)合益適純可更有效降低LDL-C和TC。 2.聯(lián)合治療對(duì)頸動(dòng)脈粥樣硬化斑塊可能有一定的逆轉(zhuǎn)作用。 3.高TC、LDL-C水平對(duì)頸動(dòng)脈斑塊的形成可能有一定的促進(jìn)作用。 4.觀察組與對(duì)照組相比較，不良反應(yīng)發(fā)生率比較差異無(wú)統(tǒng)計(jì)學(xué)意義（P＞0.05）。
[Abstract]:Objective to study more and more clinical evidence that hyperlipidemia is the main risk factor for coronary atherosclerotic heart disease and cerebrovascular disease. To compare the efficacy and safety of Yishichun combined with orderable drugs in regulating lipid, and to explore a more suitable scheme for secondary prevention of stroke in patients with cerebral infarction. Participants and methods patients with cerebral infarction were selected from June 1st 2012 to June 30th 2013 in Department of Neurology, second affiliated Hospital of Suzhou University. All patients were accompanied with carotid atherosclerotic plaque and hyperlipidemia TC5.69 mmol / L LDL-C3.10 mmol / L, including 61 males and 37 females; The average age was 61.32 鹵7.36 years old. All patients were not treated with statin or hydrochloric acid lipid-lowering drugs before entering the group. There was no abnormal liver and kidney function and no acute severe infection. There was no history of surgery and trauma, no metabolic and endocrine diseases, and no history of malignant tumor within 3 months. There was no significant difference in age and other general clinical data (P 0.05). All the subjects were given routine drug treatment, including anti-platelet aggregation. Drugs for lowering blood pressure (except acute cerebral infarction). All 98 patients in the group were randomly divided into two groups: control group (n = 98) and observation group (n = 49). The control group was treated by oral administration of rosuvastatin (product name can be determined, Chinese medicine accurate character J20090091). AstraZeneca Pharmaceutical Co., Ltd. 10mg / d, the observation group oral Risuvastatin 10mg Ezeimex (product name, import drug registration certificate no.: H20080132). The patients were followed up for 24 weeks and 12 weeks to 24 weeks, respectively, to monitor the blood lipid levels of four serum total cholesterol (TCs) in the abdominal blood of the outpatients. Triglyceride (TGN), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), apolipoprotein (Apo-Bn). Hypersensitive C-reactive protein (hs-CRP), liver function (alt, AST, CK), and carotid Doppler ultrasound were performed at 24 weeks. The maximum area of atherosclerotic plaques in the common carotid artery was measured and IMT was measured within 1.0 cm from the common carotid artery bifurcation. The main endpoint events (death) and secondary endpoint events (new stroke) were recorded. Results the levels of LDL-C and Apo-B were significantly lower in the two groups than before treatment (P < 0.05). The LDL-C in the observation group was significantly lower than that in the control group (P < 0.05). The decrease of TC and Apo-B was significantly lower than that of control group (P < 0.05). After treatment, the maximum area of carotid atherosclerotic plaque in observation group was significantly lower than that before treatment (P < 0.05), and before treatment in control group. After treatment, the area of carotid atherosclerotic plaque did not change significantly (P > 0.05). The level of hs-CRP decreased significantly after treatment (P < 0.05). There was no statistical difference between the observation group and the control group (P > 0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P > 0.05). Conclusion 1. Both 10 mg and 10 mg of codeine can significantly reduce the level of blood lipid, but the combination of Kedalin and Isochon can effectively reduce LDL-C and TCC. 2. 2. Combined therapy may have a reversal effect on carotid atherosclerotic plaque. 3. High level of TCU LDL-C may promote carotid plaque formation. 4. There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P > 0.05).
【學(xué)位授予單位】：蘇州大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R743.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 譚小平;;阿司匹林聯(lián)合辛伐他汀防治缺血性腦血管病臨床研究[J];海峽藥學(xué);2012年03期

2 肖四海;宋巧鳳;劉春榮;王小玲;;阿托伐他汀聯(lián)合依折麥布對(duì)糖尿病患者內(nèi)皮功能及炎癥指標(biāo)的影響[J];河北醫(yī)藥;2012年11期

3 王成章;魏士賢;馬麗蘋(píng);;他汀類藥物與腦卒中的研究進(jìn)展[J];解放軍保健醫(yī)學(xué)雜志;2006年04期

4 朱紅;李東野;夏勇;徐通達(dá);馬先麗;張延斌;潘德鋒;;依折麥布聯(lián)合辛伐他汀對(duì)極高危人群強(qiáng)化降脂的作用及安全性評(píng)價(jià)[J];南京醫(yī)科大學(xué)學(xué)報(bào)(自然科學(xué)版);2010年09期

5 龐文躍;;冠心病高�；颊邚�(qiáng)化降脂治療的臨床意義——IDEAL試驗(yàn)的啟示[J];中國(guó)實(shí)用內(nèi)科雜志;2007年06期

6 張旺;;阿司匹林在治療心腦血管性疾病中的應(yīng)用[J];現(xiàn)代診斷與治療;2008年06期

7 胥麗霞;孟秀君;侯率;費(fèi)學(xué)萍;康志偉;高素蘭;徐瑞珍;孫美波;宋曉;楊崗;吳敬湘;王秀清;;缺血性腦血管病二級(jí)預(yù)防阿司匹林藥物應(yīng)用狀況調(diào)查[J];中國(guó)醫(yī)科大學(xué)學(xué)報(bào);2010年12期

8 李瑩,陳志紅,周北凡,李義和,武陽(yáng)豐,劉小清,趙連成,麥勁壯,楊軍,石美玲,田秀珍,關(guān)渭全,于學(xué)海,陳磊;我國(guó)中年人群血清TC/HDL-C比值與缺血性和出血性腦卒中發(fā)病危險(xiǎn)性[J];中華神經(jīng)科雜志;2005年05期

9 ;各類腦血管疾病診斷要點(diǎn)[J];中華神經(jīng)科雜志;1996年06期

10 文川;徐浩;;The New Strategy for Modulating Dyslipidemia:Consideration from Updated Understanding on High-Density Lipoprotein[J];Chinese Journal of Integrative Medicine;2011年06期

本文編號(hào)：1448138